Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden

European Journal of Endocrinology

Volumn 166, Issue 6, 2012, Pages 1021-1029

  Thunander, Maria ^a,b   Törn, Carina ^b   Petersson, Christer ^c,d   Ossiansson, Birger ^c   Fornander, Jan ^c   Landin Olsson, Mona ^b  

^a Central Hospital   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c Primary Care ^*  (Sweden)

^d R and D County Council   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUTAMATE DECARBOXYLASE ANTIBODY; PANCREAS ISLET CELL ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD SAMPLING; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HORMONE ACTION; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SWEDEN;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANALYSIS OF VARIANCE; AREA UNDER CURVE; AUTOANTIBODIES; AUTOIMMUNITY; BIOLOGICAL MARKERS; BODY MASS INDEX; C-PEPTIDE; CARBOXY-LYASES; DIABETES MELLITUS; DIAGNOSIS, DIFFERENTIAL; FASTING; FEMALE; GLUTAMIC ACID; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; STATISTICS, NONPARAMETRIC; SWEDEN;

EID: 84862740212     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0797     Document Type: Article

References (46)

1. Faber OK & Binder C. B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment. Diabetologia 1977 13 263-268. (doi:10.1007/BF01219710)
2. Steffes MW, Sibley S, Jackson M & Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003 26 832-836. (doi:10.2337/diacare.26.3. 832)
3. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Oglesby A, Hayes C & Spinas GA. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model. Current Medical Research and Opinion 2004 20 (Suppl 1) S59-S66. (doi:10.1185/030079904X2024)
4. Marchetti P, Lupi R, Del Guerra S, Bugliani M, D'Aleo V, Occhipinti M, Boggi U, Marselli L & Masini M. Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control. Diabetes Care 2009 32 (Suppl 2) S178-S183. (doi:10.2337/dc09-S306)
5. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M & Blonde L. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 MetCTZD). Diabetes Care 2009 32 1224-1230. (doi:10.2337/dc08-2124)
6. Arnqvist HJ, Littorin B, Nystrom L, Schersten B, Ostman J, Blohme G, Lithner F & Wibell L. Difficulties in classifying diabetes at presentation in the young adult. Diabetic Medicine 1993 10 606-613. (doi:10.1111/j.1464-5491. 1993.tb00132.x)
7. Gilliam LK, Brooks-Worrell BM, Palmer JP, Greenbaum CJ &Pihoker C. Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetes. Journal of Autoimmunity 2005 25 244-250. (doi:10.1016/j.jaut.2005.09. 013)
8. Thunander M, Petersson C, Jonzon K, Fornander J, Ossiansson B, Torn C, Edvardsson S & Landin-Olsson M. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Research and Clinical Practice 2008 82 247-255. (doi:10.1016/j.diabres.2008.07.022)
9. Brophy S, Brunt H, Davies H, Mannan S & Williams R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database of Systematic Reviews 2007 18 CD006165.
10. Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC &Colman PG. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006 29 970-975. (doi:10.2337/dc05-2101)
11. Lutgens MW, Meijer M, Peeters B, Poulsen ML, Rutten MJ, Bots ML, van der Heijden GJ & Soedamah-Muthu SS. Easily obtainable clinical features increase the diagnostic accuracy for latent autoimmune diabetes in adults: an evidence-based report. Primary Care Diabetes 2008 2 207-211. (doi:10.1016/j.pcd.2008.08.003)
12. Gjessing HJ, Matzen LE, Faber OK & Froland A. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia 1989 32 305-311. (doi:10.1007/BF00265547)
13. Report of a WHO Study Group. World Health Organisation, Tech Rep Ser no 727, 1985.
14. Bennett P & Knowler WC. Definition, diagnosis and classification of diabetes mellitus and glucose homeostasis. In Joslins Diabetes Mellitus, pp 331-339. Ed EA Kahn. Boston: Lipincott, Williams &Wilkins, 2005.
15. Alberti KG & Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine 1998 15 539-553. (doi:10.1002/(SICI)1096-9136(199807)15:7〈539::AID- DIA668〉3.0.CO;2-S)
16. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010 33 Suppl 1 S62-S69.
17. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnstrom BO, Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR & Groop LC. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999 48 150-157. (doi:10.2337/diabetes.48. 1.150)
18. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ & Eisenbarth GS. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 1998 47 1857-1866. (doi:10.2337/diabetes.47.12.1857)
19. Bingley PJ, Bonifacio E & Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003 52 1128-1136. (doi:10.2337/diabetes.52.5.1128)
20. Picardi A, Visalli N, Lauria A, Suraci C, Buzzetti R, Merola MK, Manfrini S, Guglielmi C, Gentilucci UV, Pitocco D, Crino A, Bizzarri C, Cappa M & Pozzilli P. Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes. Hormone and Metabolic Research 2006 38 668-672. (doi:10.1055/s-2006-954586)
21. Petrone A, Galgani A, Spoletini M, Alemanno I, Di Cola S, Bassotti G, Picardi A, Manfrini S, Osborn J, Pozzilli P & Buzzetti R. Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes/Metabolism Research and Reviews 2005 21 271-275. (doi:10.1002/dmrr.549)
22. Jensen R, Gilliam L, Torn C, Landin-Olsson M, Palmer J, Akesson K, Kockum I, Lernmark B, Karlsson AF, Lynch KF, Breslow N, Lernmark A & Sundkvist G. Islet cell autoantibody levels after the diagnosis of young adult diabetic patients. Diabetic Medicine 2007 24 1221-1228. (doi:10.1111/j.1464-5491.2007. 02235.x)
23. Basu R, Dalla Man C, Campioni M, Basu A, Klee G, Toffolo G, Cobelli C & Rizza RA. Effects of age and sex on postprandial glucose metabolism: differences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes 2006 55 2001-2014. (doi:10.2337/db05-1692)
24. Greenbaum CJ, Anderson AM, Dolan LM, Mayer-Davis EJ, Dabelea D, Imperatore G, Marcovina S & Pihoker C. Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care 2009 32 1839-1844. (doi:10.2337/dc08-2326)
25. Tsai EB, Sherry NA, Palmer JP & Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 2006 49 261-270. (doi:10.1007/s00125-005-0100-8)
26. Kuk JL, Saunders TJ, Davidson LE & Ross R. Age-related changes in total and regional fat distribution. Ageing Research Reviews 2009 8 339-348. (doi:10.1016/j.arr.2009.06.001)
27. Geer EB & Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gender Medicine 2009 6 (Suppl 1) 60-75. (doi:10.1016/j.genm.2009.02.002)
28. Clauson P, Linnarsson R, Gottsater A, Sundkvist G & Grill V. Relationships between diabetes duration, metabolic control and beta-cell function in a representative population of type 2 diabetic patients in Sweden. Diabetic Medicine 1994 11 794-801. (doi:10.1111/j.1464-5491.1994.tb00355.x)
29. Gottsater A, Landin-Olsson M, Fernlund P, Lernmark A &Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 1993 16 902-910. (doi:10.2337/diacare.16.6.902)
30. Tfayli H, Bacha F, Gungor N & Arslanian S. Islet cell antibody-positive versus -negative phenotypic type 2 diabetes in youth: does the oral glucose tolerance test distinguish between the two? Diabetes Care 2010 33 632-638. (doi:10.2337/dc09-0305)
31. Hillier TA & Pedula KL. Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care 2001 24 1522-1527. (doi:10.2337/diacare.24.9.1522)
32. Balasubramanyam A, Garza G, Rodriguez L, Hampe CS, Lakshmi G, Lernmark A & Maldonado MR. Accuracy and predictive value of ketosis-prone diabetes. Diabetes Care 2006 29 2575-2579. (doi:10.2337/dc06-0749)
33. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A &DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. Journal of Clinical Endocrinology and Metabolism 2005 90 493-500. (doi:10.1210/jc.2004-1133)
34. Turner R, Stratton I & Horton V. UKPDS: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997 350 1288-1293. (doi:10.1016/S0140-6736(97)03062- 6)
35. Bronstein J & Lawrence RD. Two types of diabetes mellitus, with and without available plasma insulin. BMJ 1951 1 732. (doi:10.1136/bmj.1.4709.732)
36. Rolandsson O & Palmer JP. Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes. Diabetologia 2010 53 1250-1253. (doi:10.1007/s00125-010-1713-0)
37. Gale EAM. Declassifying diabetes. Diabetologia 2006491989-1995. (doi:10.1007/s00125-006-0348-7)
38. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D & Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. New England Journal of Medicine 2005 352 2598-2608. (doi:10.1056/NEJMoa043980)
39. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS & Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004 53 250-264. (doi:10.2337/diabetes.53.1.250)
40. Landin-Olsson M, Nilsson KO, Lernmark A & Sundkvist G. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 1990 33 561-568. (doi:10.1007/BF00404145)
41. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG & Harrison LC. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005 48 2206-2212. (doi:10.1007/s00125-005-1960-7)
42. Leslie RD, Williams R & Pozzilli P. Clinical review: type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. Journal of Clinical Endocrinology and Metabolism 2006 91 1654-1659. (doi:10.1210/jc.2005- 1623)
43. Appel SJ, Wadas TM, Rosenthal RS & Ovalle F. Latent autoimmune diabetes of adulthood (LADA): an often misdiagnosed type of diabetes mellitus. Journal of the American Academy of Nurse Practitioners 2009 21 156-159. (doi:10.1111/j.1745-7599. 2009.00399.x)
44. Naik RG, Brooks-Worrell BM & Palmer JP. Latent autoimmune diabetes in adults. Journal of Clinical Endocrinology and Metabolism 2009 94 4635-4644. (doi:10.1210/jc.2009-1120)
45. Isomaa B, Almgren P, Henricsson M, Taskinen MR, Tuomi T, Groop L & Sarelin L. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 1999 22 1347-1353. (doi:10.2337/diacare. 22.8.1347)
46. Thunander M, Thorgeirsson H, Torn C, Petersson C & Landin-Olsson M. Beta-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up. European Journal of Endocrinology 2011 164 239-245. (doi:10.1530/EJE-10-0901)